drugset
drugset / Trial / NCT03767218

Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase

NCT03767218 ↗

Phase 3 Completed 71 enrolled University Hospital Brussels
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomised controlled open-label clinical trial to compare the outcome parameters after ovarian stimulation using recombinant-human FSH (follicle stimulating hormone), starting on day 2 of the cycle versus start in the late follicular phase of the cycle.

Timeline

Start
2018-11-01
Primary completion
2022-05-27
Completion
2022-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganirelix Protein / enzyme biologic 0.25 mg —
Subject recombinant-human FSH Protein / enzyme biologic 225 iu —
Background Triptorelin Other / unclassified 0.2 mg —

Indications

female infertility